5MG/GLP-3  5MG (10MG)

Combining Cagrilintide (a long-acting amylin analogue) and GLP-3 (a triple agonist of GLP-1, GIP, and glucagon receptors) represents what many researchers call the “next frontier” of metabolic pharmacology.
While GLP-3 is already a major factor on its own, adding Cagrilintide creates a multi-pathway synergy that targets appetite and energy expenditure from four or five different angles simultaneously.

Key Benefits of the Combination:

The primary appeal of this stack is synergy. Because they hit different receptors, they can often achieve greater results at lower individual doses, potentially mitigating side effects.

• Unprecedented: GLP-3 alone has shown up to 24% effectiveness in specific clinical trials. Adding Cagrilintide (which showed significant results in the “CagriSema” trials) aims to push those numbers even higher, potentially rivaling bariatric surgery.
• Dual-Action Satiety: * GLP-3 slows gastric emptying and signals fullness via the brainstem.
  • Cagrilintide mimics amylin, a hormone that induces “satiation” (the feeling of being finished with a meal) and further slows digestion.
• Glucagon & Metabolic Rate: GLP-3’s glucagon component increases energy expenditure (calorie burning), while Cagrilintide helps regulate glucose and prevents the “rebound hunger” often seen when blood sugar dips.
• Improved Glycemic Control: Both peptides significantly improve insulin sensitivity, making this combo a powerhouse for reversing markers of Type 2 Diabetes and Metabolic Syndrome.

How the Synergy Works

Peptide | Receptors Targeted | Primary Effect: GLP-3 | GLP-1, GIP, Glucagon | Appetite suppression, insulin secretion, and increased thermogenesis.
Cagrilintide | Amylin, Calcitonin | Early meal termination (satiation) and delayed gastric emptying.